The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure

被引：42

作者：

Bhatt, Deepak L. ^{[1
]}

Verma, Subodh ^{[2
]}

Braunwald, Eugene ^{[1
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Dept Surg,Div Cardiac Surg, Toronto, ON, Canada

来源：

CELL METABOLISM | 2019年 / 30卷 / 05期

关键词：

D O I：

10.1016/j.cmet.2019.10.008

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

In a randomized trial of patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin markedly reduced mortality and worsening heart failure (McMurray et al., 2019). Remarkably, these benefits seemed to be similar in people with and without diabetes. These data usher in a new paradigm in the treatment of heart failure.

引用

页码：847 / 849

页数：3

共 13 条

[11]

Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI [10.1056/NEJMoa1812389, 10.1056/NEJMc1902837]

[12] SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J].

Zelniker, Thomas A. ;

Wiviott, Stephen D. ;

Raz, Itamar ;

Im, Kyungah ;

Goodrich, Erica L. ;

Bonaca, Marc P. ;

Mosenzon, Ofri ;

Kato, Eri T. ;

Cahn, Avivit ;

Furtado, Remo H. M. ;

Bhatt, Deepak L. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Wilding, John P. H. ;

Sabatine, Marc S. .

LANCET, 2019, 393 (10166) :31-39

[13] Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes [J].

Zelniker, Thomas A. ;

Braunwald, Eugene .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (15) :1845-1855

← 1 2 →